CancerVista
Monitor cancer with precision.
From a blood draw.
A ctDNA liquid biopsy MRD test that can detect solid tumor recurrence months before imaging.
Validated In-House IVD Test
Built on rigorous evidence
Clinical utility of MRD testing is established in many different cancers such as colorectal, breast and lung cancer. See liquidbiopsyinfo.com, our liquid biopsy and MRD evidence base, for detailed evidence by cancer.
3.3 × 10⁻⁶
Limit of Detection (LoD)
For solid tumor MRD
>99%
Variant Detection Specificity
Genotyping / variant detection
10–15
Business Days
Turnaround time for an interpreted report
>600
Genotyped Genes
Comprehensive panel coverage
Did you know? Clinical evidence for MRD exists for most cancers
Clinical evidence for ctDNA-based MRD testing now spans nearly every major solid tumor type, and grows every year as new peer-reviewed studies are published.
liquidbiopsyinfo.com is our independent, continuously updated library of the clinical evidence behind liquid biopsy and MRD testing, organized by cancer type so you can find the studies relevant to your patients.
Explore the Evidence Base at liquidbiopsyinfo.com →
Decisions you could not make before
22 solid tumor types
Find your tumor type:
Three steps. Precise results. Confident decisions.
Characterize
Draw 20ml of peripheral blood or submit a tissue sample. No specialized lab setup or added training required.
Monitor
Serial testing at each follow-up watches for recurrence in the asymptomatic window, often months before imaging can detect it.
Decide
Our results allow you to make confident decisions about the next steps in treatment or follow-up care.
Built by a physician, for patients and colleagues
"Every oncologist has had the moment: imaging finally confirms a relapse you suspected months ago. LIQOMICS exists because that delay costs lives."
Detect recurrence. Earlier.
Request our test protocol or speak directly with a LIQOMICS specialist.